Keyphrases
Metastatic Renal Cell Carcinoma (mRCC)
100%
Sunitinib
100%
Long-term Response
100%
Long-term Responders
37%
Progression-free Survival
25%
Median Progression-free Survival
25%
Complete Response
25%
Bone Metastasis
25%
Lung Metastasis
25%
Progression-free
25%
Clinical Trials
12%
Median Overall Survival
12%
Univariate Analysis
12%
Survival Analysis
12%
Patient Characteristics
12%
In(III)
12%
Partial Response
12%
Durable Response
12%
Risk Status
12%
Poor Risk
12%
Stable Disease
12%
Best Response
12%
Objective Response
12%
Adverse Prognostic Factor
12%
MSKCC
12%
Pharmacology, Toxicology and Pharmaceutical Science
Sunitinib
100%
Kidney Metastasis
100%
Progression Free Survival
75%
Bone Metastasis
25%
Lung Metastasis
25%
Clinical Trial
12%
Overall Survival
12%
Diseases
12%